Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M197,910Revenue $M48,196Net Margin (%)18.5Altman Z-Score2.7
Enterprise Value $M203,091EPS $1.4Operating Margin %24.9Piotroski F-Score6
P/E(ttm)22.7Beneish M-Score-2.8Pre-tax Margin (%)24.9Higher ROA y-yN
Price/Book3.010-y EBITDA Growth Rate %2.6Quick Ratio1.9Cash flow > EarningsY
Price/Sales4.25-y EBITDA Growth Rate %4.4Current Ratio2.1Lower Leverage y-yY
Price/Free Cash Flow15.5y-y EBITDA Growth Rate %-8.8ROA % (ttm)5.3Higher Current Ratio y-yN
Dividend Yield %3.4PEG5.2ROE % (ttm)12.4Less Shares Outstanding y-yY
Payout Ratio %77.0Shares Outstanding M6,167ROIC % (ttm)11.7Gross Margin Increase y-yY

Gurus Latest Trades with PFE

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
PFENWQ Managers 2015-06-30 Reduce-0.67%$33.46 - $35.44
($34.36)
$ 32.66-5%Reduce 26.23%4,372,936
PFEJoel Greenblatt 2015-06-30 Reduce-0.25%$33.46 - $35.44
($34.36)
$ 32.66-5%Reduce 48.07%1,024,564
PFEKahn Brothers 2015-06-30 Reduce-0.21%$33.46 - $35.44
($34.36)
$ 32.66-5%Reduce 2.00%1,774,875
PFEFirst Eagle Investment 2015-06-30 Reduce-0.08%$33.46 - $35.44
($34.36)
$ 32.66-5%Reduce 18.06%4,315,476
PFEDodge & Cox 2015-06-30 Reduce-0.05%$33.46 - $35.44
($34.36)
$ 32.66-5%Reduce 3.30%45,234,031
PFEKen Fisher 2015-06-30 Add0.04%$33.46 - $35.44
($34.36)
$ 32.66-5%Add 1.95%31,816,749
PFECharles Brandes 2015-06-30 Reduce-0.03%$33.46 - $35.44
($34.36)
$ 32.66-5%Reduce 1.12%6,054,883
PFEJohn Keeley 2015-06-30 Add0.02%$33.46 - $35.44
($34.36)
$ 32.66-5%Add 30.77%129,055
PFEMario Gabelli 2015-06-30 Reduce-0.01%$33.46 - $35.44
($34.36)
$ 32.66-5%Reduce 8.54%819,901
PFEJames Barrow 2015-06-30 Add0.01%$33.46 - $35.44
($34.36)
$ 32.66-5%Add 0.50%55,354,855
PFEDavid Dreman 2015-06-30 Reduce$33.46 - $35.44
($34.36)
$ 32.66-5%Reduce 1.10%24,926
PFERichard Pzena 2015-06-30 Add$33.46 - $35.44
($34.36)
$ 32.66-5%Add 0.01%2,159,818
PFEKahn Brothers 2015-03-31 Reduce-0.39%$31.16 - $35.05
($33.51)
$ 32.66-3%Reduce 3.83%1,811,016
PFEJames Barrow 2015-03-31 Reduce-0.32%$31.16 - $35.05
($33.51)
$ 32.66-3%Reduce 12.24%55,080,222
PFENWQ Managers 2015-03-31 Reduce-0.16%$31.16 - $35.05
($33.51)
$ 32.66-3%Reduce 6.64%5,927,532
PFEJoel Greenblatt 2015-03-31 Add0.15%$31.16 - $35.05
($33.51)
$ 32.66-3%Add 38.84%1,972,788
PFECharles Brandes 2015-03-31 Reduce-0.07%$31.16 - $35.05
($33.51)
$ 32.66-3%Reduce 2.37%6,123,536
PFEDavid Dreman 2015-03-31 Add0.03%$31.16 - $35.05
($33.51)
$ 32.66-3%Add 70.38%25,202
PFEMario Gabelli 2015-03-31 Reduce-0.01%$31.16 - $35.05
($33.51)
$ 32.66-3%Reduce 5.80%896,431
PFEDodge & Cox 2015-03-31 Reduce-0.01%$31.16 - $35.05
($33.51)
$ 32.66-3%Reduce 0.89%46,776,959
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

PFE is held by these investors:


News about PFE:

Articles On GuruFocus.com
Inflation Data Shows Continued Lack of Price Stability Progress Aug 28 2015 
Pfizer Nears Completion of Hospira Acquisition Aug 26 2015 
Kyle Bass Focuses on Fuel, Pharmaceutical Stocks in Second Quarter Aug 24 2015 
The Best Companies of the Pharmaceuticals Industry – August 2015 Aug 18 2015 
Kahn Brothers Reduces Stake in Old Republic International Aug 05 2015 
Five Undervalued Dow Stocks to Research – August 2015 Aug 05 2015 
Five Undervalued Companies with a Low Beta – August 2015 Aug 04 2015 
GDP Growth Improves to 2.3% for the Second Quarter Aug 04 2015 
Pfizer Increases Annual Earnings Guidance for 2015 Jul 29 2015 
It’s Not Too Late To Buy Gilead Sciences Jul 17 2015 

More From Other Websites
Pfizer (PFE) Gains on Label Expansion Efforts for Ibrance Aug 28 2015
The 4 Stocks That Held Down the DJIA on Friday Aug 28 2015
What You Need To Know About 2 New S&P 500 Members Aug 28 2015
Credit Suisse's 8 Pharmaceutical Stocks With 'Significant' Upside Aug 28 2015
Dow 30 Stock Roundup: 3M Lowers 2015 Earnings Outlook, JNJ Subsidiary Sells Splenda Aug 28 2015
Research and Markets: China Latanoprost Market Investigation Report 2010-2019 Aug 28 2015
Amgen wins approval for second biotech cholesterol drug Aug 27 2015
Amgen wins approval for second biotech cholesterol drug Aug 27 2015
FDA proposes adding suffixes to distinguish biosimilar drug names Aug 27 2015
Cramer: China & biotech - it's complicated Aug 27 2015
Activision Blizzard, United Continental Holdings Set to Join the S&P 500 Aug 27 2015
Trade S&P 500 changes Aug 27 2015
Tracking today's volatility Aug 27 2015
At the close: Stocks snap back Aug 27 2015
FDA proposes adding suffixes to distinguish biosimilar drug names Aug 27 2015
FDA proposes adding suffixes to distinguish biosimilar drug names Aug 27 2015
Deutsche Bank Says Stick With Top Stocks Growing Dividends Aug 27 2015
More dividend cuts looming? Aug 26 2015
MannKind And Afrezza: Can The Drug Cure The Company? Aug 26 2015
Short Sellers Have Mixed Feelings on Major Pharma Aug 26 2015

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

User Comments

SEENSCO
ReplySEENSCO - 1 year ago
PFE is trading at the low end of our short-term valuation range ($29-$36) and significantly below our Fair Value estimate of $42.41.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK